As of November 6, 2026, Collegium Pharmaceutical Inc is a publicly traded company (Nasdaq: COLL); its largest reported holder is Millennium, with 7.4% on Schedule 13G/A of October 8, 2026, then Janus Henderson (5.8%) (Schedule 13G/A, October 8, 2026).
Is this your company?
About to sign with, pay or invest in Collegium Pharmaceutical Inc? See the free Snapshot first.
Free to see. No signup.
Is Collegium Pharmaceutical Inc a real, registered company?
- Collegium Pharmaceutical Inc files with the SEC under CIK 1267565 (its SEC filings).
- Its shares are listed under the ticker COLL on Nasdaq (SEC company record).
- Incorporated in Virginia; business address in Stoughton, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Collegium Pharmaceutical Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is John Fallon, Director (Form 8-K filed 2026-04-07). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Millennium (filed 2026-10-08).
Who are Collegium Pharmaceutical Inc's owners and officers?
Collegium Pharmaceutical Inc: incorporated in Virginia; business address in Stoughton, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-30).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-30 | Vanguard Capital Management | 4.97% |
| Schedule 13G/A, 2026-10-29 | Principal Global Investors | 4.7% |
| Schedule 13G/A, 2026-10-08 | Millennium Management LLC | 7.4% |
| Schedule 13G, 2026-08-24 | Millennium Management LLC | 5.6% |
| Schedule 13G, 2026-08-14 | Fuller & Thaler Asset Management, Inc. | 5.03% |
| Schedule 13G, 2026-08-05 | Principal Global Investors | 5% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.01% |
| Schedule 13G, 2026-05-15 | Janus Henderson Group PLC | 5.8% |
| Schedule 13G/A, 2026-05-15 | Eventide Asset Management, LLC | 4.5% |
| Schedule 13G/A, 2026-05-14 | Renaissance Technologies LLC | 4.53% |
| Schedule 13G, 2026-05-12 | Integrated Core Strategies (US) LLC | 4.7% |
| Schedule 13G, 2026-05-08 | Invesco LTD. | 5% |
Questions about who owns Collegium Pharmaceutical Inc
Who owns Collegium Pharmaceutical Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Collegium Pharmaceutical Inc: Millennium Management LLC (7.4%, Schedule 13G/A, filed 2026-10-08), Janus Henderson Group PLC (5.8%, Schedule 13G, filed 2026-05-15), Fuller & Thaler Asset Management, Inc. (5.03%, Schedule 13G, filed 2026-08-14) and Invesco LTD. (5%, Schedule 13G, filed 2026-05-08).
Who are the largest shareholders of Collegium Pharmaceutical Inc?
By the share each holder's latest filing reports, the largest holders of Collegium Pharmaceutical Inc on this page are Millennium Management LLC (7.4%), Janus Henderson Group PLC (5.8%) and Fuller & Thaler Asset Management, Inc. (5.03%).
When did Millennium Management LLC buy into Collegium Pharmaceutical Inc?
The filings give report dates, not purchase dates. The earliest filing from Millennium Management LLC on this page is the Schedule 13G, filed 2026-08-24, reporting 5.6%; its latest, Schedule 13G/A filed 2026-10-08, reports 7.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Collegium Pharmaceutical Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Collegium Pharmaceutical Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Collegium Pharmaceutical Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-07 | John Fallon | Director | departed |
Which insiders own Collegium Pharmaceutical Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 3,132,743 shares (10.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-08-15).
- Rubric Capital Management LP, a 10% owner: 3,132,743 shares (10.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-08-15).
- , the chief executive and president: 197,864 shares (0.64% of shares outstanding) (Form 4, 2026-02-12).
- , the chief financial officer and executive vice president: 147,282 shares (0.47% of shares outstanding) (Form 4, 2026-02-12).
- , a director: 115,706 shares (0.37% of shares outstanding), 83,952 held directly and 31,754 indirectly (Form 4, 2026-05-20).
Shares outstanding: 31,075,424 as of 2026-10-31, from the company's latest SEC cover page.
How much has Collegium Pharmaceutical Inc raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-05-12).
Keep reading
More on Collegium Pharmaceutical Inc and the records around it.
Collegium Pharmaceutical Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes May 2026
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
- PRINCIPAL GLOBAL INVESTORS also filed stake reports on 19 other companies: Brookfield Infrastructure Partners L.P. (Oct 2026), Hyatt Hotels Corp (Oct 2026), National Healthcare Properties, Inc. (Oct 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/collegium-pharmaceutical